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Distribution and activity of doxorubicin combined with SDZ PSC 833 in
mice with P388 and P388/DOX leukaemia
T Colombo, 0 Gonzalez Paz and M D'Incalci
Laboratory of Cancer Chemotherapy, Mario Negri Institute for Pharmacological Research, Via Eritrea 62, 20157 Milan, Italy.
Summary SDZ PSC 833 (PSC 833) is a non-immunosuppressive analogue of cyclosporin A and is a potent
modifier of P-glycoprotein (P-gp)-mediated multidrug resistance. The present study was undertaken to evaluate
whether doxorubicin (DOX) pharmacokinetic and anti-tumour activity on P388- and P388/DOX-resistant
leukaemia was modified by PSC 833 pretreatment. P388- or P388/DOX-bearing mice were given PSC 833
intraperitoneally 30 min before an intravenous injection of DOX. The levels of DOX were determined by a
high-performance liquid chromatography method in leukaemic cells and in normal tissues (heart, lung, liver,
small intestine, kidney and spleen). In all tissues, DOX concentrations were significantly increased in mice
pretreated with PSC 833. The difference was greatest in P-gp-overexpressing P388/DOX cells, the DOX area
under the curve being approximately seven times greater after PSC 833 and DOX than after DOX alone. In
P388 cells the difference was approximately 2.5 times, as in the majority of normal tissues. As expected DOX
levels in P388 cells were higher than in P388/DOX cells in mice treated with DOX alone, whereas after PSC
833 and DOX the levels of DOX were similar in the two leukaemic lines. In spite of this PSC 833 was unable
to reverse the resistance to DOX of P388/DOX leukaemia in vivo, suggesting that mechanisms other than P-gp
expression are responsible for resistance.
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Cyclosporin A or its non-immunosuppressive analogue PSC
833 has very good activity in reversing the resistance to
several anti-cancer agents of in vitro growing cells with a
multidrug resistance phenotype, i.e. those expressing the
membrane P-gp (Twentyman and Bleehen, 1991; Boesch et
al., 1991a; Friche et al., 1992; Keller et al., 1992; Boesch and
Loor, 1994).
Preclinical information on the combination ofcyclosporins
with anti-cancer drugs in vivo is limited. Recent reports
indicate that cyclosporin A (Colombo et al., 1994) or PSC
833 (Gonzalez et al., 1995) pretreatment significantly
increases the retention of DOX in mouse normal tissues
such as liver, kidney, intestine, adrenals and heart. The
changes in DOX distribution may be related to the
cyclosporins' ability to inhibit P-gp, thus reducing the rate
of drug transport out of the cells. P-gp is not only expressed
in resistant tumour cells, but also in many normal tissues
(Fojo et al., 1987; Thiebaut et al., 1987; Croop et al., 1989;
Endicott and Ling, 1989; Ford and Hait, 1990) where it
probably helps defend against potentially toxic xenobiotics.
Cyclosporin A or PSC 833 were reported to increase the
toxicity of DOX in normal mice, suggesting that DOX doses
should be reduced when used with either of these drugs
(Colombo et al., 1994; Gonzalez et al., 1995). Recent clinical
data indicate that, although PSC 833 alone does not cause
any evident toxicity, when combined with DOX it strongly
enhances its toxicity, so the DOX dose must be reduced
(Erlichman et al., 1993; Giaccone et al., 1994). However,
reducing the DOX dose also lowers the chances of
therapeutic success.
It is reasonable to assume that, if the cyclosporin-induced
increase in tissue retention of DOX is similar in normal and
neoplastic tissues, the combination of DOX and cyclosporins
is unlikely to improve the therapeutic index of DOX. Instead,
if the cyclosporin treatment raises the DOX concentration
more in the resistant tumour than in the normal tissues, the
combination could be advantageous even if DOX doses have
to be reduced.
The lack of adequate preclinical studies to answer this
question, which has obvious clinical importance, prompted us
to undertake this study. The aim of the study is to obtain
information on how PSC 833 influences the distribution of
DOX in normal tissues and in P388 and P388/DOX tumour
cells, and to check the anti-tumoral activity of DOX or DOX
combined with PSC 833 against these murine leukaemias.
Materials and methods
Drugs
PSC 833, kindly provided by Sandoz, Basle, Switzerland, was
freshly dissolved in ethanol and olive oil (0.05:10). DOX,
kindly provided by Pharmacia-Farmitalia-Carlo Erba, Milan,
Italy, was freshly dissolved in distilled water.
Northern blot analysis of the mdrl gene
Total cellular RNA was extracted by the guanidinium
isothiocyanate
-caesium chloride centrifugation method
(Gros et al., 1986). For Northern blot analysis 20 Mg of
total RNA was fractionated on a 1% agarose gel containing
6.7% formaldehyde and transferred to nylon membrane
(Gene-screen plus New England Nuclear). The filters were
hybridised for 16 h at 42'C in 50% formamide, 10% dextran
sulphate, 1M sodium chloride, 1% sodium dodecyl sulphate
(SDS), 100 Mg ml-' denatured salmon sperm DNA and 106
c.p.m. ml-' denatured 32P-labelled probe. After hybridisation
the filters were washed sequentially in 2 x SSC at room
temperature and in 2 x SSC 1% SDS at 65°C. The probe used
was the 1.3 kb EcoRI/Sall insert of pcDR.3 containing the
murine mdr gene (Gros et al., 1986). The probe was labelled
with 32p using the multiprime DNA labelling system and
[32P]dCTP (Amersham, UK).
In vivo experiments
BDF1 male mice (20+2 g body weight) obtained from
Charles River Italia, Calco, Italy, were used for these
experiments. Procedures involving animals and their care
are conducted in conformity with the institutional guidelines
that are in compliance with national (D.L. n. 116, G.U.,
suppl. 40, 18 February 1992) and international laws and
policies (EEC Council Directive 86/609, OJ L 358,1, Dec. 12,
Correspondence: M D'Incalci
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November 19951987; NIH Guide for the Care and Use of Laboratory
Animals, NIH Publication No. 85-23, 1985).
P388 and its subline resistant to DOX (P388/DOX) were
kindly provided by Dr Pesenti, Pharmacia-Farmitalia-Carlo
Erba, Milan. The parental line and the resistant subline were
passaged weekly through DBA and BDFI mice. P388 and
P388/DOX cell lines grew at the same rate, both producing
ascites; by transplanting the same number ofcells the survival
was similar for both tumour cell lines.
For evaluation of anti-tumour activity one million
leukaemia cells were inoculated intraperitoneally (i.p.) and
mice were treated on day 1 after tumour transplant. DOX
was injected intravenously (i.v.) with different schedules and
PSC 833 was given i.p. 30 min before DOX. The time interval
between the administration of PSC 833 and DOX was
selected on the basis of our previous studies (Colombo et al.,
1994; Gonzalez et al., 1995). Anti-tumour activity was
evaluated by recording the mean and median survival time
of the mice. Changes in survival are expressed as the
percentage increase in median lifespan of treated mice over
untreated controls (T/C).
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For the pharmacokinetic studies PSC 833 was injected i.p.
at a dose of 12.5 mg kg-'. DOX was injected i.v. at the dose
of 10 mg kg-1, corresponding approximately to 30 mg m-2,
30 min after PSC 833. At 24, 48, 72 and 96 h after DOX,
four mice per time point were exsanguinated under light ether
anaesthesia and serum and tissues (heart, lung, liver, small
intestine, kidneys and spleen) were removed and frozen at
-20'C until use. The ascitic fluid was removed, leukaemic
cells counted, washed and centrifuged in order to have a
pellet of 108 cells per sample. The pellets were frozen at
-20'C until analysis.
Analytical assay
DOX and metabolites were quantified by high-performance
liquid chromatography (HPLC) with fluorimetric detection
according to a previously described technique (Broggini et al.,
1984), with minor modifications. After homogenisation in
water, tissue samples, with daunorubicin added as internal
standard, were deproteinised with silver nitrate (33%),
extracted with 8 ml of propanol and centrifuged at 3000
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Figure 1 Disappearance curves of DOX in tissues of mice treated with DOX alone, 10 mg kg-' i.v. (0) or with PSC 833, 12.5 mg
kg-' i.p. (0) in mice bearing P388 leukaemia (0 O), and its subline resistant to DOX (O- - -0). Bars represent s.e.; not
visible when smaller than the symbols. For further details see Table I.
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r.p.m.; the organic phase was evaporated to dryness under
vacuum. The pellet of leukaemia cells was resuspended in 1
ml of distilled water then processed as described for tissue
samples. Extracts were injected into the HPLC with
fluorescence detection at an excitation wavelength of 475
nm and an emission of 580 nm. Separation was achieved with
an isocratic solvent system ofwater-acetonitrile-phosphoric
acid 0.1 M using a 30 cm yBondapak C18 (10-pm) column.
Recovery of DOX extraction after adding known amount of
drug to cell or tissue homogenate was 85-90% and the
sensitivity was 10 ng ml-' for cells and 20 ng g-' for tissue.
DOX plus PSC 833 were higher than in P388 cells after DOX
alone. In P388/DOX and P388 cells concentrations of DOX
were similar after DOX plus PSC 833.
Anti-tumour activity
P388 and P388/DOX leukaemia-bearing mice were treated
with DOX alone or with DOX plus PSC 833. On the basis of
the distribution studies of DOX and on toxicity data already
obtained by this laboratory in tumour-free mice (Gonzalez et
al., 1995), we had initially used DOX doses in the range of
Pharmacokinetic and statistical analysis
The area under the curve of drug concentration as a function
of time (AUC, ,ug ml-' or g x h) was calculated by the
trapezoidal method up to 96 h. Statistical significance was
assessed by Duncan' s test.
Results
DOX tissue distribution
Figure 1 shows the tissue levels ofDOX in mice bearing P388
leukaemia (solid line) and its subline resistant to DOX
(dotted line). DOX levels were higher in all tissues of mice
treated with DOX plus PSC 833 than in mice receiving DOX
alone. Figure 2 shows the DOX levels in P388 and P388/
DOX leukaemic cells. DOX reached a higher concentration
in leukaemic cells of mice pretreated with PSC 833; in DOX-
resistant cells, DOX concentrations after PSC 833 were
similar to those in sensitive cells.
The DOX AUC in leukaemic cells and in different tissues
of mice bearing P388 and P388/DOX, treated with DOX
alone or in combination with PSC 833 are illustrated in Table
I. In all tissues DOX levels were higher (P<0.01) in mice also
given PSC 833; DOX concentrations in P388/DOX cells after
Cells
1-
4e
0
0
0
x
0
nA
24
t--
1
0 - --,- -
-~~~
o - D
48 72 96
Time (h)
Figure 2 Disappearance curves of DOX in leukaemic cells of
mice treated with DOX alone, 10 mg kg-' i.v. (0) or with PSC
833, 12.5 mg kg-' i.p. (0) in mice bearing P388 leukemia
(0-0), and its subline resistant to DOX (0- - -0). Bars
represent s.e.; not visible when smaller than the symbols. For
further details see Table I.
Table I AUC 24-96 h (ygml-1 x h or jggg1 x h) in BDF1 male mice given DOX alone or in combination with PSC-833 (four mice per
group)
P388 P388/DOX
DOX PSC12.5+DOX DOX PSC12.5+DOX
Leukaemic cells 15.7 ±2.1 39.3 ± 5.6** 5.8±0.1 43.9± 6.5**
Heart 101.4±5.01 217.6± 14.0** 138.4±12.7 276.3±13.3**
Lung 402.6±86.9 865.1±152.7** 432.3+49.1 1099.7±76.2**
Liver 163.1 ± 10.9 327.1 ±44.7** 200.7+26.1 323.8+ 17.5**
Small intestine 147.7 ±9.9 389.2± 53.0** 178.8 ± 26.0 562.4±71.9**
Kidney 301.7+26.4 587.4± 43.6** 506.0±64.4 592.1 ± 52.2*
Spleen 1123.9 ± 74.7 1772.6 ± 130** 1270.7 ±112 2178.4 ±207**
*P<0.05. **P<0.01 vs DOX alone, Duncan's test.
Table II Effect of PSC 833 on anti-tumour activity of DOX in P388 and P388/DOX-bearing mice treated 1 day after tumour transplant
P388 P388/DOX
Dose Mean Median TIC Mean Median TIC
(mg kg-') ±s.e. (range) (%) ±s.e. (range) (%)
Controls 12±0.2 12(11-13) - 11±0.3 11(10-12)
PSC 12.5 11±0.2 11.5(11-12) 96 11±0.4 10.5(10-13) 95
DOX 2.5 13±0.7 13(12-18) 108 11±0.3 11(10-12) 100
DOX 5 15±0.6 14.5(14-18) 121 11±0.5 10.5(10-14) 95
DOX 10 20±0.9 20(18-25) 167 11±0.4 11(10-13) 100
PSC
+ DOX 2.5 16±1.3 15(14-25) 125 12±0.4 12(11-14) 109
PSC
+ DOX 5 22±0.6 22(21-26) 183 12±0.4 12(11-14) 109
PSC
+ DOX 10 36±4 32(26-60)a 271 15±0.4 14.5(14-17) 132
PSC 833, dissolved in a solution ofethanol (<0.05%) and olive oil was injected at the dose of 12.5 mgkg 1 i.p. 30 min before DOX i.v. a One
mouse died on day 60 from delayed toxicity, without evidence ofdisease.
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2.5-10 mg kg-', which can be combined with PSC 833
without causing toxic deaths. Table II shows the results of
treating P388 and P388/DOX leukaemia-bearing mice on day
1 after tumour transplant. DOX prolonged the survival of
P388-bearing mice in a dose-dependent manner but was
inactive against P388/DOX. PSC 833 potentiated the activity
of DOX in P388 leukaemia. The dose of 5 mg kg-1 DOX in
combination with PSC 833 was as effective as 10 mg kg-1
DOX alone. Survival time was increased most when 10 mg of
DOX and PSC 833 were given (T/C=271).
PSC 833 did not potentiate DOX activity in P388/DOX;
only marginal activity was seen when 10 mg kg-' DOX was
combined with PSC 833. Similar results were obtained
treating P388- and P388/DOX-bearing mice 4 days after
tumour implant (data not shown). In P388-bearing mice 10
mg kg-' DOX combined with PSC 833 increased survival
remarkably (T/C = 221), whereas no significant activity was
found in P388/DOX (T/C=110). Even higher DOX doses
given with PSC 833 showed no activity against P388/DOX
(Table III).
When the dose of 16.9 mg kg-' DOX was combined with
12.5 mg kg-' PSC 833 some toxic deaths were observed.
Therefore, in subsequent experiments PSC 833 doses were
reduced to 3.25 or 6.5 mg kg-' combined with 16.9 mg kg-'
DOX, which gave the maximum increase in survival of P388-
leukaemia bearing mice without toxic deaths. This regimen
showed no activity against P388/DOX.
A higher PSC 833 dose, 25 mg kg- ', dramatically
increased the toxicity of DOX with a large percentage of
toxic deaths even with only 10 mg kg-' DOX.
Northern blot analysis of the mdr-1 gene
In order to clarify our unexpected findings, we evaluated the
mdrl expression of P388 and P388/DOX maintained in vitro
or transplanted in vivo by Northern blotting analysis (see
Figure 3). P388/DOX cells presented overexpression of the
mdrl gene either in vitro or in vivo. In P388 cells mdr
expression was clearly much less than in the resistant subline.
Nevertheless in the sensitive P388 it was also detectable both
in vitro and in vivo. In P388 cells growing in vivo, which are
more relevant for our studies, the expression of mdrl
appeared to be higher than in P388 cells growing in vitro.
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Figure 3 Northern blot analysis of mdr-J expression in P388/
DOX in vivo and in vitro and in P388 in vitro and in vivo.
Discussion
Studies in normal mice showed that DOX distribution was
greatly influenced by pretreatment with either cyclosporin A
(Colombo et al., 1994) or PSC 833 (Gonzalez et al., 1995).
The present study in P388- or P388/DOX-bearing mice
confirms and extends these findings. The 2-3 times increase
in DOX AUC was similar to that described in liver, kidney,
Table m Anti-tumour activity of DOX alone or with PSC 833 in P388-and P388/DOX-bearing mice
P388 P388/DOX
Dose Mean Median TIC Mean Median TIC
(mg kg-') +s.e. (range) (%) +s.e. (range) (%)
Controls 11+0.2 11(11-12) - 11+0.4 10.5(10- 12)
PSC 3.125 12+0.7 11(10-15) 100 11+0.4 11(10-12) 105
PSC 6.25 12+0.6 11.5(11-15) 104 11+0.3 11(10-12) 105
PSC 12.5 11±0.6 11(10-14) 100 11+0.2 11(10-11) 105
DOX
10 20+0.2 19(19-20) 169 13+0.2 13(12-13) 118
16.9 23 + 0.8 23(20-25) 214 12 12(12-12) 114
20 25+1.9 26(7-27) 226 13+0.7 13(9-15) 123
PSC 3.125
+ DOX 16.9 40+9.8 27(23-83)a 250 11±2.4 11(11-12) 109
PSC 6.25
+ DOX 16.9 35±4.7 34(22-53) 314 13 +0.5 13(12-15) 124
PSC 12.5
+ DOX 16.9 28+9.3 22(6-55) 200 8+0.5 8(7-10) 76
+ DOX 20 6±0.1 6(6-7) 52 6+0.1 6(6-7) 54
PSC 25
+ DOX 10 11+3.9 6.5(6-30) 56 7+0.3 6.5(6-8) 59
Animals treated 1 day after tumour transplant; PSC dissolved in a solution ofethanol (<0.05%) and olive oil. Each group contained 6 8 mice.
a One mouse died on day 83, from delayed toxicity without evidence ofdisease.
81
A
169DOX and SDZ PSC 833 in mice
a0 T Colombo et al
870
intestine and heart of normal mice. In lungs, which were not
examined in previous studies, pretreatment with PSC 833 also
increased DOX retention with DOX AUC approximately
double that after DOX alone.
These changes in DOX distribution induced by PSC 833
treatment may well be due to the inhibition of P-gp, which
appears to be expressed in these tissues (Kaye, 1993;
Gottesman, 1993). However other, not yet identified,
transport membrane proteins may be inhibited by PSC 833.
The lack of any real difference in DOX plasma levels in mice
receiving DOX alone or in combination with PSC 833, and
the findings of previous detailed studies on the urinary and
faecal elimination of DOX and its metabolites (Gonzalez et
al., 1995) suggest that PSC 833 mainly affects tissue
distribution.
The main aims of this study were to investigate whether
PSC 833 increased the DOX AUC in tumour cells,
particularly those overexpressing P-gp, and whether the
increase was greater than in normal tissues of the same
mice. The finding that PSC 833 raises DOX intracellular
concentrations much more in the P388/DOX tumour than in
other tissues is the first evidence that a selectivity of action of
a reversing agent can be obtained in vivo towards mdr cancer
cells. After administration of the combination of PSC 833
and DOX the concentrations of DOX in P388/DOX cells
were even higher than in P388 cells after DOX alone.
Therefore it was expected that PSC 833 in combination with
DOX might reverse the resistance of P388/DOX leukaemia.
Instead, the combination did not significantly improve. The
most likely explanation is that the resistance ofP388/DOX to
DOX is not only due to overexpression of P-gp, with
consequent lower drug retention, but to other mechanisms as
well. Resistance to DOX might be due to mutation of
topoisomerase II, which can become less susceptible to
inhibitors of the enzyme (Capranico et al., 1986; Sikic,
1993; Isaacs et al., 1995).
Possibly, therefore, P388/DOX leukaemia is not the most
suitable experimental model for investigating whether a
reversing agent restores sensitivity to DOX or other
chemotherapeutic agents.
However, P388/DOX leukaemia is one of the most widely
used models for studies on drugs that counteract mdr
(Grandi et al., 1987; Radel et al., 1988; Boesch et al.,
1991b; Tsuruo and Tomida, 1995). Boesch et al. (1991b)
reported that PSC 833 significantly prolonged the median
survival time in P388/DOX leukaemia. They specified the
source of the leukaemia, which was the same as ours, thus
excluding the possibility that the differences were due to
differences in the two tumour lines. The routes and dosage
schedules, however, were different. They gave PSC 833 orally
at doses of 25 or 50 mg kg-' and DOX i.p. at the dose of 2
mg kg-' on days 0, 4 and 8 after tumour implant, whereas
we gave PSC 833 i.p. (12.5 mg kg-') 30 min before DOX i.v.
(2.5, 5, 10 mg kg-'). To clarify this point we also assessed the
effect of oral PSC 833 given by the same oral dosage
schedules as Boesch et al., administering DOX i.v. at doses of
1.99, 2.51, 3.15 and 4 mg kg-' (data not shown). However,
the combination had no activity, T/C being 115 compared
with 100 for controls receiving either PSC 833 or the vehicle.
Possibly therefore the better results reported by Boesch et al.
are due to the fact that they gave DOX by the i.p. route.
Since they did not report the effects of DOX alone at doses
higher than 2 mg kg-1 we cannot establish whether PSC 833
improved the therapeutic index in their conditions. We did
not repeat the experiments giving DOX i.p. because by this
route DOX causes chemical peritonitis. In our opinion the
strong inflammation that is certainly associated with the i.p.
injection of DOX makes it difficult to interpret the
therapeutic outcome in i.p. transplanted leukaemias. In
addition, results in mice given DOX i.p. are of scant value
as the i.p. route cannot be used in cancer patients on account
of the irritation caused by the drug.
The finding that PSC 833 can greatly increase DOX
concentrations in a DOX-resistant tumour indicates that PSC
833 is a potentially effective mdr reversing agent for tumours
whose mechanism of resistance is entirely related to P-gp
expression. However most advanced human drug-resistant
tumours, probably like the mouse P388/DOX leukaemia, do
not appear to have one single mechanism of resistance, but a
variety of different ones, including transport mechanisms,
alterations of the molecular target (e.g. mutations of DNA
topoisomerases in the case of anthracyclines) and also more
general mechanisms related to the triggering of the process of
cell death after drug-induced perturbations (e.g. increased
expression of the bcl-II gene). The more advanced and
pretreated the tumour the greater are the chances it will
contain cellular clones with multiple and complex resistance
mechanisms. It is therefore not surprising that the results so
far with reversing agents in extensively pretreated cancer
patients highly resistant to chemotherapy have been
disappointing (Rodenburg et al., 1991; Raderer and
Scheithauer, 1993; D'Incalci, 1995).
An additional finding of the present study is that when
PSC 833 was combined with DOX in the sensitive P388
leukaemia there was marked potentiation of anti-tumour
activity, with an increase in survival time compared with that
of DOX alone. This unexpected finding prompted us to verify
whether P388 cells were expressing the mdr gene. Northern
blot analysis showed that mdr gene mRNA was detectable in
P388 cells, although at a very low level compared with P388/
DOX cells. The expression of the mdr gene explains why PSC
833 enhances DOX distribution in these cells. The
enhancement, however, was similar or slightly higher than
that found in the normal tissues, which also express the mdr
gene. However in terms of the therapeutic index the
superiority of the combination of DOX and PSC 833 over
DOX alone in P388-leukaemia bearing mice appears
questionable. In fact, for example, survival time of mice
treated with 5 mg kg-' DOX associated with PSC 833
appeared similar to that of mice given 10 mg kg-' DOX
alone. In conclusion the results shown in the present study do
not support the clinical use of PSC 833 combined with DOX
for resistant tumours. It is still open to question whether the
combination of DOX, at a reduced dose, with PSC 833 can
be advantageous over a high dose of DOX alone for some
moderately resistant tumours whose resistance mechanism is
supposedly only linked to mdr expression.
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